Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Pro

Showing results (101-110 of 187) with videos related to

Pageof 19
Sort By:
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphomaYasuhiro Oki, Daniela Buglio, Michelle Fanale, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
British Journal of Haematology|January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer CenterQi Liu, Luis Fayad, Fernando Cabanillas, et al.
British Journal of Haematology|June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Lei Feng, et al.
Journal of the American Academy of Dermatology|April 2, 2020
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patientsMaria L Espinosa, Morgan T Nguyen, Amaia Saenz Aguirre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
British Journal of Haematology|July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
British Journal of Haematology|July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky diseaseFelipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Pageof 19

Showing results (101-110 of 187) with videos related to

Sort By:
Pageof 19
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphomaYasuhiro Oki, Daniela Buglio, Michelle Fanale, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
British Journal of Haematology|January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer CenterQi Liu, Luis Fayad, Fernando Cabanillas, et al.
British Journal of Haematology|June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Lei Feng, et al.
Journal of the American Academy of Dermatology|April 2, 2020
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patientsMaria L Espinosa, Morgan T Nguyen, Amaia Saenz Aguirre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphomaJohn F Seymour, Barbara Pro, Lillian M Fuller, et al.
British Journal of Haematology|July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphomaJason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
British Journal of Haematology|July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky diseaseFelipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Pageof 19